Sale

Europe Biosimilar Market

Europe Biosimilar Market Size, Trends, Growth, Share, Report: By Molecule: Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Others; By Manufacturing Type: In-house Manufacturing, Contract Manufacturing; By Indication; Regional Analysis; Competitive Landscape; 2024-2032

Europe Biosimilar Market Outlook 

The Europe biosimilar market reached a value of almost USD 5,751.95 million in the year 2023. The biosimilar industry is further expected to grow at a CAGR of 25% between 2024 and 2032 to reach a value of almost USD 42,855.44 million by 2032.

 

Europe Biosimilar Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The Europe biosimilar market is driven by the initiatives by the European Medicines Agency (EMA). The market within the region exhibits the most mature market in the world and continues to gain momentum. The industry is further anticipated to have rapid growth in the next five years as a number of major biologics are scheduled to lose patent protection within the region. Germany was the largest biosimilars market in Europe in the year 2020.

 

Properties and Applications

Biosimilars are referred to as the biotherapeutic products, which are similar to already licensed reference biologics, on the basis of quality, safety, and efficiency. These are manufactured and approved in alignment with the stringent laws of the European Medicines Agency (EMA). The Europe biosimilar market is divided on the basis of molecule into:

 

Europe Biosimilar Market by Indication

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

  • Infliximab
  • Insulin Glargine
  • Epoetin Alfa
  • Etanercept
  • Filgrastim
  • Somatropin
  • Rituximab
  • Follitropin Alfa
  • Others

On the basis of manufacturing type, the industry is divided into:

  • In-house Manufacturing
  • Contract Manufacturing

On the basis of indication, the Europe biosimilar market is segregated into:

  • Autoimmune Diseases
  • Blood Disorder
  • Diabetes
  • Oncology
  • Growth Deficiency
  • Female Infertility

The report also covers the regional markets of biosimilar in Europe like Italy, Germany, France, the United Kingdom, Spain, and the rest of Europe.

 

Europe Biosimilar Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The Europe biosimilar market is driven by the short marketing times as launching a biosimilar does not involve extensive marketing as the security and efficacy profile of their branded counterparts has already been established. The market is further aided as the product is less expensive as compared to their branded counterparts owing to no requirement for extensive research and testing, saving both money and time; thus, reducing overall costs. Many blockbuster biologics are anticipated to lose their patent protection in this decade. The expiration of patents and other intellectual property rights is projected to generate huge opportunities for biosimilar manufacturers, further aiding the industry growth in the region over the forecast period.

A significant amount of the European population is over the age of 65 years, accounting for about one-fifth of the total population within the region. This has led to a significant increase in the burden of lifestyle diseases in Europe. The rising prevalence of diseases like oncology, autoimmune diseases, and diabetes in Europe is also expected to impel the industry growth of biosimilars during the forecast period.

 

Competitive Landscape

The report gives a detailed analysis of the following key players in the Europe biosimilar market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Pfizer Inc.
  • Celltrion Inc.
  • Novartis AG
  • AMGen Inc.
  • Eli Lilly and Company.
  • Samsung Bioepis
  • Sanofi SA
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. 

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Molecule
  • Manufacturing Type
  • Indication
  • Region
Breakup by Molecule
  • Infliximab
  • Insulin Glargine
  • Epoetin Alfa
  • Etanercept
  • Filgrastim
  • Somatropin
  • Rituximab
  • Follitropin Alfa
  • Others
Breakup by Manufacturing Type
  • In-house Manufacturing
  • Contract Manufacturing
Breakup by Indication
  • Auto-Immune Diseases
  • Blood Disorder
  • Diabetes
  • Oncology
  • Growth Deficiency
  • Female Infertility
Breakup by Region
  • Italy
  • Germany
  • France
  • United Kingdom
  • Spain
  • Rest of Europe
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Price Analysis
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Pfizer Inc.
  • Celltrion Inc.
  • Novartis AG
  • AMGen Inc.
  • Eli Lilly and Company.
  • Samsung Bioepis
  • Sanofi SA
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Europe
7    Opportunities and Challenges in the Market
8    Europe Biosimilar Market Analysis

    8.1    Key Industry Highlights
    8.2    Europe Biosimilar Historical Market (2018-2023) 
    8.3    Europe Biosimilar Market Forecast (2024-2032)
    8.4    Europe Biosimilar Market by Molecule
    8.4.1    Infliximab
            8.4.1.1    Historical Trend (2018-2023)
            8.4.1.2    Forecast Trend (2024-2032)
        8.4.2    Insulin Glargine
            8.4.2.1    Historical Trend (2018-2023)
            8.4.2.2    Forecast Trend (2024-2032)
        8.4.3    Epoetin Alfa
            8.4.3.1    Historical Trend (2018-2023)
            8.4.3.2    Forecast Trend (2024-2032)
        8.4.4    Etanercept
            8.4.4.1    Historical Trend (2018-2023)
            8.4.4.2    Forecast Trend (2024-2032)
        8.4.5    Filgrastim
            8.4.5.1    Historical Trend (2018-2023)
            8.4.5.2    Forecast Trend (2024-2032)
        8.4.6    Somatropin
            8.4.6.1    Historical Trend (2018-2023)
            8.4.6.2    Forecast Trend (2024-2032)
        8.4.7    Rituximab
            8.4.7.1    Historical Trend (2018-2023)
            8.4.7.2    Forecast Trend (2024-2032)
        8.4.8    Follitropin Alfa
            8.4.8.1    Historical Trend (2018-2023)
            8.4.8.2    Forecast Trend (2024-2032)
        8.4.9    Others
    8.5    Europe Biosimilar Market by Manufacturing Type
        8.5.1    In-house Manufacturing
            8.5.1.1    Historical Trend (2018-2023)
            8.5.1.2    Forecast Trend (2024-2032)
        8.5.2    Contract Manufacturing
            8.5.2.1    Historical Trend (2018-2023)
            8.5.2.2    Forecast Trend (2024-2032)
    8.6    Europe Biosimilar Market by Indication
        8.6.1    Auto-Immune Diseases
            8.6.1.1    Historical Trend (2018-2023)
            8.6.1.2    Forecast Trend (2024-2032)
        8.6.2    Blood Disorder
            8.6.2.1    Historical Trend (2018-2023)
            8.6.2.2    Forecast Trend (2024-2032)
        8.6.3    Diabetes
            8.6.3.1    Historical Trend (2018-2023)
            8.6.3.2    Forecast Trend (2024-2032)
        8.6.4    Oncology
            8.6.4.1    Historical Trend (2018-2023)
            8.6.4.2    Forecast Trend (2024-2032)
        8.6.5    Growth Deficiency
            8.6.5.1    Historical Trend (2018-2023)
            8.6.5.2    Forecast Trend (2024-2032)
        8.6.6    Female Infertility
            8.6.6.1    Historical Trend (2018-2023)
            8.6.6.2    Forecast Trend (2024-2032)
    8.7    Europe Biosimilar Market by Country
        8.7.1    Italy
        8.7.2    Germany
        8.7.3    France
        8.7.4    United Kingdom
        8.7.5    Spain
        8.7.6    Rest of Europe
9    Regional Analysis
    9.1    Italy
        9.1.1    Historical Trend (2018-2023)
        9.1.2    Forecast Trend (2024-2032)
    9.2    Germany
        9.2.1    Historical Trend (2018-2023)
        9.2.2    Forecast Trend (2024-2032)
    9.3    France
        9.3.1    Historical Trend (2018-2023)
        9.3.2    Forecast Trend (2024-2032)
    9.4    United Kingdom
        9.4.1    Historical Trend (2018-2023)
        9.4.2    Forecast Trend (2024-2032)
    9.5    Spain
        9.5.1    Historical Trend (2018-2023)
        9.5.2    Forecast Trend (2024-2032)
    9.6    Rest of Europe
        9.6.1    Historical Trend (2018-2023)
        9.6.2    Forecast Trend (2024-2032)
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyers Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    Key Indicators for Demand
    10.4    Key Indicators for Price
11    Value Chain Analysis
12    
Competitive Landscape
    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    Pfizer Inc.
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Financial Summary
            12.2.1.5    Certifications
        12.2.2    Celltrion Inc.
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Financial Summary
            12.2.2.5    Certifications
        12.2.3    Novartis AG
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Financial Summary
            12.2.3.5    Certifications
        12.2.4    AMGen Inc. 
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Financial Summary
            12.2.4.5    Certifications
        12.2.5    Eli Lilly and Company.
            12.2.5.1    Company Overview
            12.2.5.2    Product Portfolio
            12.2.5.3    Demographic Reach and Achievements
            12.2.5.4    Financial Summary
            12.2.5.5    Certifications
        12.2.6    Samsung Bioepis
            12.2.6.1    Company Overview
            12.2.6.2    Product Portfolio
            12.2.6.3    Demographic Reach and Achievements
            12.2.6.4    Financial Summary
            12.2.6.5    Certifications
        12.2.7    Sanofi SA
            12.2.7.1    Company Overview
            12.2.7.2    Product Portfolio
            12.2.7.3    Demographic Reach and Achievements
            12.2.7.4    Financial Summary
            12.2.7.5    Certifications
        12.2.8    Others
15    Key Trends and Developments in the Market

 

List of Key Figures and Tables

1.    Europe Biosimilar Market: Key Industry Highlights, 2018 and 2032
2.    Europe Biosimilar Historical Market: Breakup by Molecule (USD Billion), 2018-2023
3.    Europe Biosimilar Market Forecast: Breakup by Molecule (USD Billion), 2024-2032
4.    Europe Biosimilar Historical Market: Breakup by Indication (USD Billion), 2018-2023
5.    Europe Biosimilar Market Forecast: Breakup by Indication (USD Billion), 2024-2032
6.    Europe Biosimilar Historical Market: Breakup by Manufacturing Type (USD Billion), 2018-2023
7.    Europe Biosimilar Market Forecast: Breakup by Manufacturing Type (USD Billion), 2024-2032
8.    Europe Biosimilar Historical Market: Breakup by Country (USD Billion), 2018-2023
9.    Europe Biosimilar Market Forecast: Breakup by Country (USD Billion), 2024-2032
10.    Europe Biosimilar Market Structure

Key Questions Answered in the Report

In 2023, the Europe biosimilar market attained a value of nearly USD 5,751.95 million.

In the forecast period of 2024-2032, the market in Europe is projected to grow at a CAGR of 25%.

By 2032, the market is estimated to reach a value of about USD 42,855.44 million.

The major market drivers include the rising prevalence of autoimmune diseases and diabetes, low costs of biosimilar, and rising geriatric population.

The key trends guiding the market are the expiry of various patents, short marketing times of biosimilars, and the increasing approvals of biosimilars by healthcare bodies.

The major countries in the Europe market are Italy, Germany, France, the United Kingdom, and Spain, among the rest of Europe.

The significant molecule segments of biosimilar considered in the market report are infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab, and follitropin alfa, among others.

The major indications considered in the market report are auto-immune diseases, blood disorders, diabetes, oncology, growth deficiency, and female infertility.

In-house manufacturing and contract manufacturing are the most significant manufacturing types in the industry.

The major players in the industry are Pfizer Inc., Celltrion Inc., Novartis AG, Merck Sharp & Dohme Corp., Eli Lilly and Company, and Samsung Bioepis, Accord-UK Ltd., among others.

Analyst Review

The Europe biosimilar market attained a value of USD 5,751.95 million in the year 2023 driven by the growing geriatric population in the region. Aided by the low cost of the product and the expected expiry of various patents, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 25%. The market is projected to reach USD 42,855.44 million by 2032.    

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its molecule, the biosimilar market can be segmented into infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab, and follitropin alfa, among others. On the basis of indication, the industry can be segmented into autoimmune diseases, blood disorder, diabetes, oncology, growth deficiency, and female infertility. In-house manufacturing and contract manufacturing are the major manufacturing types in the market. The major regional markets for biosimilar market are Italy, Germany, France, the United Kingdom, Spain, and the rest of Europe, with Germany accounting for the largest share of the market. The key players in the above industry include Pfizer Inc., Celltrion Inc., Novartis AG, AMGen Inc., Eli Lilly and Company, and Samsung Bioepis, Sanofi SA, among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.  

Purchase Full Report

Mini Report

$ 2639     $2399
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 4399     $3999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 5829     $5299
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 6929     $6299
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER